516 related articles for article (PubMed ID: 33186490)
1. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
Cappelli LC; Bingham CO
Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
[TBL] [Abstract][Full Text] [Related]
2. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
[TBL] [Abstract][Full Text] [Related]
3. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].
Tingry T; Massy E; Piperno M; Auroux M; Kostine M; Maillet D; Amini-Adle M; Fabien N; Estublier C; Goncalves D; Girard N; Confavreux CB
Bull Cancer; 2021 Jun; 108(6):643-653. PubMed ID: 33902919
[TBL] [Abstract][Full Text] [Related]
4. Rheumatic Complications of Immune Checkpoint Inhibitors.
Ghosh N; Bass AR
Rheum Dis Clin North Am; 2022 May; 48(2):411-428. PubMed ID: 35400368
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
6. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
Kostine M; Rouxel L; Barnetche T; Veillon R; Martin F; Dutriaux C; Dousset L; Pham-Ledard A; Prey S; Beylot-Barry M; Daste A; Gross-Goupil M; Lallier J; Ravaud A; Forcade E; Bannwarth B; Truchetet ME; Richez C; Mehsen N; Schaeverbeke T;
Ann Rheum Dis; 2018 Mar; 77(3):393-398. PubMed ID: 29146737
[TBL] [Abstract][Full Text] [Related]
7. Rheumatic Complications of Immune Checkpoint Inhibitors.
Ghosh N; Bass AR
Med Clin North Am; 2021 Mar; 105(2):227-245. PubMed ID: 33589099
[TBL] [Abstract][Full Text] [Related]
8. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.
Melissaropoulos K; Klavdianou K; Filippopoulou A; Kalofonou F; Kalofonos H; Daoussis D
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403289
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.
Singh N; Shahane A; Sparks JA; Bitoun S; Cappelli LC
Rheum Dis Clin North Am; 2024 May; 50(2):269-279. PubMed ID: 38670725
[TBL] [Abstract][Full Text] [Related]
10. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
Steven NM; Fisher BA
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079
[TBL] [Abstract][Full Text] [Related]
11. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
Leipe J; Mariette X
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
[TBL] [Abstract][Full Text] [Related]
12. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
Narváez J; Juarez-López P; LLuch J; Narváez JA; Palmero R; García Del Muro X; Nolla JM; Domingo-Domenech E
Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists.
Pacholczak-Madej R; Kosałka-Węgiel J; Kuszmiersz P; Mituś JW; Püsküllüoğlu M; Grela-Wojewoda A; Korkosz M; Bazan-Socha S
Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981837
[TBL] [Abstract][Full Text] [Related]
14. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
[TBL] [Abstract][Full Text] [Related]
15. Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients.
Richter MD; Crowson C; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U
Arthritis Rheumatol; 2019 Mar; 71(3):468-475. PubMed ID: 30281202
[TBL] [Abstract][Full Text] [Related]
16. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
Zhong H; Zhou J; Xu D; Zeng X
Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
[TBL] [Abstract][Full Text] [Related]
17. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
Hyun JW; Kim KH; Kim SH; Kim HJ
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
[TBL] [Abstract][Full Text] [Related]
18. Treatment of rheumatic adverse events of cancer immunotherapy.
Reid P; Cappelli LC
Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101805. PubMed ID: 36539321
[TBL] [Abstract][Full Text] [Related]
19. [Rheumatological complications of immune checkpoint inhibitor therapy].
Lazarou I; Fernandez E
Rev Med Suisse; 2020 Mar; 16(685):504-507. PubMed ID: 32167253
[TBL] [Abstract][Full Text] [Related]
20. Rheumatologic immune checkpoint inhibitor-related adverse events.
Defoe M; Bermas BL
Curr Opin Rheumatol; 2023 May; 35(3):141-148. PubMed ID: 36912045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]